Results 151 to 160 of about 389,587 (260)

NeuroSuite for Long‐Term Functional and Structural Studies of Air‐Liquid Interface Cerebral Organoids

open access: yesAdvanced Science, EarlyView.
NeuroSuite provides a modular hardware‐software platform integrating Neuroweb and NeuroMaps to enable long‐term, in situ electrophysiological interrogation of air–liquid interface organoid slices while preserving tissue architecture. Its components can be used together or independently to capture real‐time activity, spatial network dynamics, and ...
Belquis Haider   +14 more
wiley   +1 more source

Microbial dysbiosis and inferred functional profiling reveals the potential role of <i>Methylobacterium</i> in prostate cancer. [PDF]

open access: yesFront Cell Infect Microbiol
Al Shareef ZM   +11 more
europepmc   +1 more source

PCA [PDF]

open access: yes, 2019
openaire   +1 more source

Engineering Immunoregenerative Therapy via an Immunomodulatory Binary Pharmacology Hydrogel Depot for Prolonged Allograft Survival

open access: yesAdvanced Science, EarlyView.
An immunomodulatory hydrogel (iGEL) forms spontaneously upon subcutaneous injection, acting as a tissue‐adhesive depot. It releases anti‐rejection and regenerative agents in response to inflammation, suppressing T‐cell activity, promoting vascular repair, and restoring allograft function without systemic immunosuppression.
Ning Wang   +14 more
wiley   +1 more source

Single‐Cell Dissection of Therapy‐Induced Remodeling Uncovers a Fibroblast‐Driven Immunosuppressive Niche and Targetable Vulnerabilities in Lethal Prostate Cancer

open access: yesAdvanced Science, EarlyView.
Single‐cell longitudinal profiling reveals that androgen‐deprivation therapy induces a DPT+ fibroblast‐complement axis that suppresses macrophage inflammation and drives CD8+ T cell exhaustion in prostate cancer. Concurrently, resistant epithelial subpopulations persist and engage TSPAN1‐ and NRXN1‐mediated programs promoting CRPC and neuroendocrine ...
Yang Chen   +19 more
wiley   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy